According to a new report, published by KBV research, The Global Point of Care Molecular Diagnostics Market size is expected to reach $4.1 billion by 2030, rising at a market growth of 10.2% CAGR during the forecast period.
The Assays & Kits segment is generating the highest revenue share in the Global Point of Care Molecular Diagnostics Market by Product & Service in 2022, achieving a market value of $1.9 billion by 2030. For sites of care, including hospital critical care units, outpatient clinics, physician offices, and community health posts, POC molecular diagnostic tests and kits are specially created. The point-of-care molecular diagnostics market is expected to increase due to the ongoing need for and regular purchases of assays and kits.
The Hospitals & ICUs segment has shown the growth rate of a CAGR of 10.4% during (2023 - 2030). Rising illnesses, growing patient populations, and cutting-edge technological tools are driving this market. The market potential is expanding as healthcare practitioners increasingly use point-of-care molecular testing to diagnose illness in hospitals and intensive care units accurately.
The RT-PCR segment is leading the Global Point of Care Molecular Diagnostics Market by Technology in 2022, achieving a market value of $2.6 billion by 2030. The widespread use of COVID-19 tests and other respiratory infectious disorders is responsible for the segment’s growth. In the next years, the availability of several RT-PCR and dPCR methods would propel the segment's expansion.
The Hospital-acquired Infections segment is showcasing a CAGR of 9.7% during (2023 - 2030). Healthcare-Acquired A person may get very ill if the infection enters their bloodstream, lungs, skin, urinary system, or digestive tract. These infections may last very long and are also quite challenging to cure. Such conditions have the potential to be fatal in the worst circumstances. The incidence of ventilator-associated events (VAEs), central line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), and methicillin-resistant Staphylococcus aureus (MRSA) bacteremia was much more significant in 2021 compared to 2019.
The North America market dominated the Global Point of Care Molecular Diagnostics Market by Region in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $1.5 billion by 2030. The Europe market is experiencing a CAGR of 9.9% during (2023 - 2030). Additionally, The Asia Pacific market would showcase a CAGR of 10.7% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/point-of-care-molecular-diagnostics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd., Qiagen N.V., Danaher Corporation, Bio-Rad Laboratories, Inc., BioMerieux S.A., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., and Nova Biomedical Corporation
By Product & Service
By End User
By Technology
By Application
By Geography
Companies Profiled
Unique Offerings 
